 This study evaluated the combination of two immunotherapy drugs, Dervolumab and Tremolimumab, in patients with advanced neuroendocrine neoplasms, NENs. The results showed that this combination had some effectiveness in treating certain types of NENs, such as those with G1 or G2 gastrointestinal tumours, G1 or G2 pancreatic tumours, and G3 gastroentropancreatic tumours. However, the combination did not show any effectiveness in treating typical or atypical lung carcinoids. Additionally, the combination did not have any correlation with PD-L1 expression, which is often used to predict how well a patient will respond to immunotherapy treatments. This article was authored by J. Captavila, J. Hernando, a tool, and others.